Charles River Laboratories (CRL) Tops Q3 EPS by 36c ; Offers Guidance
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $281.67 --0%
EPS Growth %: +21.8%
Financial Fact:
Loss from discontinued operations, net of tax: 342K
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +21.8%
Financial Fact:
Loss from discontinued operations, net of tax: 342K
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q3 EPS of $2.72, $0.36 better than the analyst estimate of $2.36. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $1 billion.
GUIDANCE:
Charles River Laboratories sees FY2023 EPS of $10.50-$10.70, versus the consensus of $10.56.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- BofA Securities Reiterates Underperform Rating on HubSpot Inc (HUBS)
- Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
